News

Green light for stem cell study
Enlarge image

Clinical TrialsUK

Green light for stem cell study

15.08.2012 - The British stem cell specialist ReNeuron has received the go-ahead for its phase I trial with disabled stroke patients.

After having reviewed the safety data from the first two dose cohorts, the Data Safety Monitoring Board (DSMB) has recommended to continue the PISCES trial with ReN001. ReNeuron’s ReN001 cell therapy for stroke consists of a neural stem cell line. Until now, no adverse side effects have been found in the review period. Six patients have been included in the trial, the first 18 months ago. “We are delighted that the DSMB have given a favourable recommendation to proceed to the higher and penultimate dose in the PISCES stroke trial,” said ReNeuron’s chief executive Michael Hunt. The study is testing the safety and tolerability of the treatment of ascending doses of the ReN001 cells in patients with moderate to severe functional neurological impairments from their strokes in what is the world’s first fully regulated clinical trial. In June this year, the firm revealed that the first five PISCES patients showed reductions in neurological impairment and spasticity. These improvements were sustained in the longer-term. If everything goes on as planned, ReNeuron could apply for a phase II study in 2013.

http://www.european-biotechnology-news.com/news/news/2012-03/green-light-for-stem-cell-study.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

BusinessSwedenFrance

02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • NEOVACS (F)1.25 EUR15.74%
  • SCANCELL HOLDINGS (UK)38.25 GBP14.18%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-53.97%
  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • HYBRIGENICS (F)1.86 EUR44.2%
  • GALAPAGOS (B)51.13 EUR36.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-56.7%
  • CYTOS (CH)0.61 CHF-39.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.35 EUR517.6%
  • WILEX (D)4.30 EUR465.8%
  • ADOCIA (F)69.01 EUR432.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • THROMBOGENICS (B)5.32 EUR-70.2%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015